Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Bausch + Lomb acquires AcuFocus ➤ Study: novel drug delivery system sees less inflammation with preserved drops ➤ Meibomian gland atrophy common among cataract patients, study finds ➤ mRNA technology investigated for gene therapy to treat blindness ➤ Studies find new bionic vision system offers improved outcomes ➤ ASCRS news and events
➤ Clinical trial for new cataract surgery technology ➤ Topline results from Phase 2 trial investigating treatment for persistent corneal epithelial defect ➤ Update on sustained-release glaucoma implant and Glaukos cornea programs ➤ First patient enrolled in Phase 3 trial for presbyopia drop ➤ ASCRS news and events
➤ FDA approves NDA for IOP-lowering drug ➤ NDA submitted for presbyopia drop ➤ IND accepted for investigational treatment of persistent corneal epithelial defect ➤ Topline results from Phase 2 study of novel sedation drug for cataract surgery ➤ First patient enrolled in Phase 3 trial for investigational TED therapy ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ FDA accepts NDA for pupil dilation spray ➤ NDA for new glaucoma drug accepted ➤ PMA application submitted to FDA for new IOL ➤ Data report: 12-month efficacy seen from single mechanical MGD treatment ➤ Acquisition of company developing drugs for rare ophthalmic diseases ➤ ASCRS news and events
➤ NDA submitted to FDA for drug that reverses mydriasis ➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis ➤ FDA approves IND for research to move forward on RP gene therapy ➤ Phase 2 study to treat geographic atrophy begins ➤ Study: Weaning patients off of AMD treatments compared ➤ Possible geographic atrophy treatment explored ➤ ASCRS news and events
➤ NDA submitted for new, topical dry eye disease treatment ➤ IND submitted for persistent corneal epithelial defect treatment ➤ IND filed for dry eye disease treatment ➤ Study: Investigational topical drop reduces inflammation in anterior uveitis cases ➤ Alcon completes acquisition of Aerie ➤ ASCRS news and events
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ Phase 1/2a results for suprachoroidal wet AMD treatment ➤ Enrollment complete for two Phase 2 trials investigating dry eye therapies disease ➤ Phase 2b study for drug-eluting contact lens begins ➤ Healthcare company acquires biopharmaceutical company developing ophthalmic treatments ➤ Development and commercialization licensing agreement ➤ ASOA podcast features dry eye info for the practice ➤ ASCRS news and events
➤ Topline results from Phase 3 study of atropine for myopia progression ➤ Phase 3 results for novel glaucoma drop ➤ Positive results from two Phase 3 studies for patients with RVO ➤ Phase 3 results for cell therapy treating macular telangiectasia type 2 ➤ Single injection of investigational compound for DME improves BCVA ➤ FDA accepts BLA for ophthalmic bevacizumab ➤ Mobile phone attachment developed for ophthalmic clinical trials ➤ ASCRS news and events
➤ FDA accepts NDA for ‘first-of-its-kind’ anti-inflammatory for dry eye ➤ Positive Phase 3 results for investigational presbyopia therapy ➤ Study: long-term visual outcomes with remote monitoring technology ➤ Companies partner to create tool to assess fall risk ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.